Abstract | BACKGROUND: CASE PRESENTATION: A description of 6 cases with relapsing HSP without significant renal involvement, treated with azathioprine are reported. All 6 cases met the classification criteria for the diagnosis of HSP, had relapsing symptoms despite corticosteroid use, were successfully treated with azathioprine and were tapered off of corticosteroids. The duration of azathioprine therapy ranged from 7-21 months and no adverse events were reported. CONCLUSIONS:
Azathioprine is effective in controlling prolonged relapsing symptoms of HSP, allowing earlier discontinuation of corticosteroids. This report shows that azathioprine can be included in the therapeutic options for relapsing HSP and is the first case series in the literature of azathioprine use in HSP without significant renal involvement.
|
Authors | Lampros Fotis, Paul V Tuttle 4th, Kevin W Baszis, Peri H Pepmueller, Terry L Moore, Andrew J White |
Journal | Pediatric rheumatology online journal
(Pediatr Rheumatol Online J)
Vol. 14
Issue 1
Pg. 37
(Jun 23 2016)
ISSN: 1546-0096 [Electronic] England |
PMID | 27333803
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Glucocorticoids
- Immunosuppressive Agents
- Azathioprine
- Prednisone
- Methylprednisolone
|
Topics |
- Azathioprine
(therapeutic use)
- Child
- Female
- Glucocorticoids
(therapeutic use)
- Humans
- IgA Vasculitis
(drug therapy)
- Immunosuppressive Agents
(therapeutic use)
- Male
- Methylprednisolone
(therapeutic use)
- Prednisone
(therapeutic use)
- Recurrence
- Treatment Failure
- Treatment Outcome
|